Terms: = Lung cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1 AND Treatment
30437 results:
1. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.
Chen F; Niu J; Wang M; Zhu H; Guo Z
Radiat Oncol; 2024 May; 19(1):67. PubMed ID: 38816745
[TBL] [Abstract] [Full Text] [Related]
2. Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway.
Zhong J; Hua Y; Zou S; Wang B
PLoS One; 2024; 19(5):e0299921. PubMed ID: 38814975
[TBL] [Abstract] [Full Text] [Related]
3. The effect of care interruptions on mortality in adults resuming antiretroviral therapy.
Moolla H; Davies MA; Davies C; Euvrard J; Prozesky HW; Fox MP; Orrell C; Von Groote P; Johnson LF;
AIDS; 2024 Jul; 38(8):1198-1205. PubMed ID: 38814712
[TBL] [Abstract] [Full Text] [Related]
4. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell lung cancer.
Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
[TBL] [Abstract] [Full Text] [Related]
5. Management and prognosis of patients with cancer of unknown primary: 20 years of experience.
Bardakçi M; Algin E; Düğeroğlu B; Bal Ö; Köş FT; Uncu D
Turk J Med Sci; 2023; 53(6):1722-1731. PubMed ID: 38813492
[TBL] [Abstract] [Full Text] [Related]
6. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study.
Dai S; Zhang Y; Tan X; Luo F; Yan X
Cancer Med; 2024 Jun; 13(11):e7256. PubMed ID: 38808952
[TBL] [Abstract] [Full Text] [Related]
8. A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters.
Sudha S; Shukla S; Husain N; Kumar H; Pandey RK; Kant S
Pol J Pathol; 2024; 75(1):25-35. PubMed ID: 38808606
[TBL] [Abstract] [Full Text] [Related]
9. Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA delivery in cancer therapy.
Hong J; Sim D; Lee BH; Sarangthem V; Park RW
J Nanobiotechnology; 2024 May; 22(1):293. PubMed ID: 38802812
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors.
Ying L; Xu L; Yang J; Zhang Q
Sci Rep; 2024 May; 14(1):12025. PubMed ID: 38797769
[TBL] [Abstract] [Full Text] [Related]
11. MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast cancer.
Iida M; Crossman BE; Kostecki KL; Glitchev CE; Kranjac CA; Crow MT; Adams JM; Liu P; Ong I; Yang DT; Kang I; Salgia R; Wheeler DL
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791148
[TBL] [Abstract] [Full Text] [Related]
12. Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study.
Chi Y; Liu S; Zhang J; Li H; Yang L; Zhang X; Li H; Li Q; Wang N; Lu M; Zhuo M
BMC Public Health; 2024 May; 24(1):1396. PubMed ID: 38789981
[TBL] [Abstract] [Full Text] [Related]
13. A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer.
Gao C; Gao C; Yuan Q
Medicine (Baltimore); 2024 May; 103(21):e38027. PubMed ID: 38788043
[TBL] [Abstract] [Full Text] [Related]
14. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Kilickap S; Ozturk A; Karadurmus N; Korkmaz T; Yumuk PF; Cicin I; Paydas S; Cilbir E; Sakalar T; Uysal M; Yesil Cinkir H; Uskent N; Demir N; Sakin A; Dursun OU; Aver B; Turhal NS; Keskin S; Tural D; Eralp Y; Bugdayci Basal F; Yasar HA; Sendur MAN; Demirci U; Cubukcu E; Karaagac M; Cakar B; Tatli AM; Yetisyigit T; Urvay S; Gursoy P; Oyan B; Turna ZH; Isikdogan A; Olmez OF; Yazici O; Cabuk D; Seker MM; Unal OU; Meydan N; Okutur SK; Tunali D; Erman M;
Medicine (Baltimore); 2024 May; 103(21):e37972. PubMed ID: 38787994
[TBL] [Abstract] [Full Text] [Related]
15. Predictive role of Naples prognostic score for survival in esophageal cancer: A meta-analysis.
Guo H; Wang T
Medicine (Baltimore); 2024 May; 103(21):e38160. PubMed ID: 38787991
[TBL] [Abstract] [Full Text] [Related]
16. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.
Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC
FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655
[TBL] [Abstract] [Full Text] [Related]
17. Exploring the mechanism of 6-Methoxydihydrosanguinarine in the treatment of lung adenocarcinoma based on network pharmacology, molecular docking and experimental investigation.
Liu X; Ren Y; Qin S; Yang Z
BMC Complement Med Ther; 2024 May; 24(1):202. PubMed ID: 38783288
[TBL] [Abstract] [Full Text] [Related]
18. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract] [Full Text] [Related]
19. cancer treatment Before and After Physician-Pharmacy Integration.
Kanter GP; Ozluk P; Chi W; Fisch MJ; Debono D; Parikh RB; Jacobson M; Bekelman JE; DeVries A
JAMA Netw Open; 2024 May; 7(5):e2412998. PubMed ID: 38780938
[TBL] [Abstract] [Full Text] [Related]
20. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
[Next]
